News Feed
- ImmunoCellular Therapeutics Issues Letter to Shareholders
- Celldex, Pfizer Split Over Brain Tumor Drug
- Surgeons Use New Tools to Treat Inoperable Brain Tumors
- A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
- Accumulation o f CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation.
- Poor drug distribution as a possible explanation for the results of the PRECISE trial.
- Added new trial: A Phase II Study of PDGFR Kinase Inhibitor (Tasigna® - nilotinib) in Biomarker-Enriched Recurrent Malignant Gliomas
- Moores UCSD Cancer Center Brain Tumor Treatment Program Launches Biomarker Clinical Study
- ImmunoCellular Therapeutics Announces 2010 Second Quarter Results (And reports 100% 1 year survival!)
- First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a mu lticenter experience.
- Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases.
- A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
- IBTA E News
- Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme.
- Scientists Develop “Designer Protein,” Opening New Door in Cancer Research
